Headquartered in Basel, Switzerland, Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue based cancer diagnostics, and a frontrunner in diabetes management. Founded in , Roche continues to search for better ways to prevent, diagnose and treat diseases and make sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life saving antibiotics, antimalarials and chemotherapy. In , the Roche Group employed about , people worldwide, invested . billion Swiss francs in R amp D and posted sales of . billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit roche.com
Quote | Roche Holding Ltd ADR (OTCMKTS:RHHBY)
Last: | $30.12 |
---|---|
Change Percent: | 0.97% |
Open: | $30.16 |
Close: | $29.83 |
High: | $30.23 |
Low: | $30.03 |
Volume: | 1,111,007 |
Last Trade Date Time: | 05/06/2024 03:00:00 am |
News | Roche Holding Ltd ADR (OTCMKTS:RHHBY)
2024-05-06 09:50:37 ET Summary Regeneron is not having a great start to 2024 as the company missed Q1 revenue and EPS estimates and received two complete response letters from the FDA for odronextamab. First quarter results were negatively impacted by lower-than-expected collabora...
2024-05-04 15:30:00 ET Read the full article on Seeking Alpha For further details see: Pharma R&D productivity seen improving for the first time in years - Deloitte
Message Board Posts | Roche Holding Ltd ADR (OTCMKTS:RHHBY)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $RHHBY News Article - New Data From Phase III HAVEN 6 Study Reinforce Favorable Safety | whytestocks | investorshangout | 07/11/2022 3:45:52 PM |
$25 coming soon!!! | OptimusPrime555 | investorshub | 06/13/2022 2:14:35 PM |
whytestocks: $RHHBY News Article - Data at the 2022 ASCO Annual Meeting Highlight Genentech's Contin | whytestocks | investorshangout | 05/24/2022 2:50:51 PM |
whytestocks: $RHHBY News Article - Roche launches the first infectious disease tests and cobas omni | whytestocks | investorshangout | 12/15/2021 5:55:50 PM |
$rhhby $40.45 v -0.2 (-0.49%) | Taurus69 | investorshub | 03/28/2021 6:39:30 PM |
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Wednesday, HOOKIPA Pharma Inc (NASDAQ:HOOK) received clearance from the FDA for its Investigational New Drug (IND) application for H...
– Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through 48 weeks – – The twice-yearly, 10-minute SC injection has th...
Monday, Roche Holdings AG (OTC:RHHBY) announced topline data from Phase 3 STARGLO study of Columvi (glofitamab) in combination ...